Evidence map›Paper›PMID 35832534›Full record

ArticleJournal of interventional cardiology2022

Clinical Factors and Outcomes When Real-World Heart Teams Overruled STS Risk Scores in TAVR Cases.

Jackson M King, Morgan T Black, Ruyun Jin, Gary L Grunkemeier, Branden R Reynolds, Brydan D Curtis, Robert W Hodson, Erika A Strehl, Sameer A Gafoor, Matthew D Forrester and 2 more

Abstract read
In one paragraph

Article in Journal of interventional cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jackson M KingElson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.
Morgan T BlackElson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.
Ruyun JinCenter for Cardiovascular Analytics, Research and Data Science, Providence Heart Institute, Providence St. Joseph Health, Portland, OR, USA.
Gary L GrunkemeierCenter for Cardiovascular Analytics, Research and Data Science, Providence Heart Institute, Providence St. Joseph Health, Portland, OR, USA.
Branden R ReynoldsProvidence Sacred Heart Medical Center, Spokane, WA, USA.
Brydan D CurtisProvidence Sacred Heart Medical Center, Spokane, WA, USA.
Robert W HodsonProvidence St. Vincent Medical Center, Portland, OR, USA.
Erika A StrehlHeart Institute, Providence St. Joseph Health, Renton, WA, USA.
Sameer A GafoorSwedish Heart and Vascular Institute, Swedish Medical Center, Seattle, WA, USA.
Matthew D ForresterProvidence Sacred Heart Medical Center, Spokane, WA, USA.
Emily J CoxProvidence Medical Research Center, Spokane, WA, USA.ORCID https://orcid.org/0000-0003-3929-3317
Michael E RingProvidence Sacred Heart Medical Center, Spokane, WA, USA.ORCID https://orcid.org/0000-0001-7353-5450

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study was conducted to determine why heart teams recommended transcatheter aortic valve replacement (TAVR) versus surgical AVR (SAVR) for patients at low predicted risk of mortality (PROM) and describe outcomes of these cases. Background: Historically, referral to TAVR was based predominately on the Society of Thoracic Surgeons (STS) risk model's PROM >3%. In selected cases, heart teams had latitude to overrule these scores. The clinical reasons and outcomes for these cases are unclear. Methods: Retrospective data were gathered for all TAVR and SAVR cases conducted by 9 hospitals between 2013 and 2017. Results: Cases included TAVR patients with STS PROM >3% ( Conclusions: Heart teams recommended TAVR in patients with STS PROM ≤3% primarily due to frailty, hostile chest, severe lung disease, and/or morbid obesity. Similar postoperative outcomes between these patients and those with STS PROM >3% suggest that decisions to overrule STS PROM ≤3% were merited and may have reduced SAVR 30-day mortality rate.

Indexed as

Aortic Valve StenosisFrailtyHeart Valve Prosthesis ImplantationLung DiseasesObesity, MorbidTranscatheter Aortic Valve ReplacementAortic ValveHumansRetrospective StudiesRisk FactorsTreatment Outcome

Identifiers

PMID35832534
PMCPMC9252751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.